Note: Descriptions are shown in the official language in which they were submitted.
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
AEROSOLIZATION APPARATUS WITH CAPSULE PUNCTURE
ALIGNMENT GUIDE
BACKGROUND
The need for effective therapeutic treatment of patients has resulted
in the development of a variety of techniques for delivering a pharmaceutical
formulation to a patient. One traditional technique involves the oral delivery
of a
pharmaceutical formulation in the form of a pill, capsule, or the like.
Inhaleable
drug delivery, where an aerosolized pharmaceutical formulation is orally or
nasally
inhaled by a patient to deliver the formulation to the patient's respiratory
tract, has
also proven to be an effective manner of delivery. In one inhalation
technique, a
pharmaceutical formulation is delivered deep within a patient's lungs where it
may
be absorbed into the blood stream. In another inhalation technique, a
pharmaceutical formulation is delivered locally to a particular site, such as
an
infected lung. Many types of inhalation devices exist including devices that
aerosolize a dry powder pharir~aceutical formulation.
One type of inhalation device aerosolizes a pharmaceutical
formulation that is stored in a capsule. For example, a dose or a portion of a
dose of
a dry powder pharmaceutical formulation may be stored in a capsule, and the
capsule may be inserted into an aerosolization device which is capable of
aerosolizing the pharmaceutical formulation. The aerosolization may be
accomplished by releasing stored energy. For example, the aerosolization may
be
accomplished by utilizing energy supplied during the user's inhalation, such
as the
flow of inhaled air, to aerosolize the pharmaceutical formulation.
Before, during or after being inserted into the aerosolization device,
the capsule is opened to expose the pharmaceutical formulation. The opening of
the
capsule may be performed, for example, by puncturing the capsule, tearing the
capsule, or separating the parts of the capsule. When the capsule is properly
opened
and when aerosolization energy is supplied, the pharmaceutical formulation is
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-2-
aerosolized so that it may be inhaled by the user and a dose or portion of a
dose of
the aerosolized pharmaceutical formulation may be delivered to the user's
respiratory tract.
However, improper use of the aerosolization device may result in the
delivery of less than the desired amount of the pharmaceutical formulation.
For
example, if a capsule is not properly or completely opened before the
aerosolization
process, the amount of pharmaceutical formulation being aerosolized may be
reduced or the flow of the aerosolized pharmaceutical formulation may not be
of
sufficiently high quality to deliver a desirable amount to the user. In
addition,
residual pharmaceutical formulation within the aerosolization apparatus can
limit
the effectiveness of the capsule puncturing process.
Therefore, it is desirable to be able to improve the effectiveness and
reproducibility of a capsule opening mechanism for an aerosolization
apparatus. It
is further desirable to be able to provide such capsule opening in a manner
than
increases the lifetime of the aerosolization apparatus.
SUM1~~IARY
The present invention satisfies these needs. In one aspect of the
invention, a capsule puncturing mechanism has a capsule alignment guide that
improves the quality and consistency of capsule punctures. Additionally, the
alignment guide extends the lifetime of the aerosolization apparatus.
In another aspect of the invention, an aerosolization apparatus
comprises a housing defining a chamber having one or more air inlets, the
chamber
being sized to receive a capsule which contains an aerosolizable
pharmaceutical
formulation; a puncturing mechanism within the housing, the puncturing
mechanism comprising an alignment guide and a puncture member, wherein the
alignment guide comprises a surface adapted to contact the capsule while the
puncture member is advanced into the capsule to create an opening in the
capsule,
and wherein at least a portion of the surface is sloped at an angle which is
less than
55 degrees relative to the longitudinal axis of the capsule; and an end
section
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-3-
associated with the housing, the end section sized and shaped to be received
in a
user's mouth or nose so that the user may inhale through the end section to
inhale
aerosolized pharmaceutical formulation that has exited the capsule through the
opening created in the capsule.
In another aspect of the invention, an aerosolization apparatus
comprises a housing defining a chamber having one or more air inlets, the
chamber
being sized to receive a capsule which contains an aerosolizable
pharmaceutical
formulation; a puncturing mechanism within the housing, the puncturing
mechanism comprising an alignment guide and a puncture member, wherein the
alignment guide comprises a surface adapted to contact the capsule while the
puncture member is advanced into the capsule to create an opening in the
capsule,
and wherein the surface comprises one or more protrusions for contacting the
capsule; and an end section associated with the housing, the end section sized
and
shaped to be received in a user's mouth or nose so that the user may inhale
through
the end section to inhale aerosolized pharmaceutical formulation that has
exited the
capsule through the opening created in the capsule.
In another aspect of the invention, a method of providing access to
an aerosolizable pharmaceutical formulation comprises providing a capsule
containing an aerosolizable pharmaceutical formulation; contacting the capsule
with
the surface of an alignment guide, the surface being sloped at an angle which
is less
than 55 degrees relative to the longitudinal axis of the capsule; and
advancing a
puncture member through the wall of the capsule to create an opening in the
capsule.
In another aspect of the invention, a method of providing access to
an aerosolizable pharmaceutical formulation comprises providing a capsule
containing an aerosolizable pharmaceutical formulation; contacting the capsule
with
the surface of an alignment guide, the surface comprising one or more
protrusions
for contacting the capsule; and advancing a puncture member through the wall
of
the capsule to create an opening in the capsule.
In another aspect of the invention, a method of aerosolizing a
pharmaceutical formulation comprises inserting a capsule containing an
aerosolizable pharmaceutical formulation in a chamber; contacting the capsule
with
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-4-
the surface of an alignment guide, the surface being sloped at an angle which
is less ,
than 55 degrees relative to the longitudinal axis of the capsule and/or having
one or
more protrusions for contacting the capsule; advancing a puncture member
through
the wall of the capsule to create an opening in the capsule; aerosolizing the
pharmaceutical formulation in the capsule by flowing air through the chamber;
and
administering the aerosolized pharmaceutical formulation to the respiratory
tract of
a user during the user's inhalation.
DRAWINGS
These features, aspects, and advantages of the present invention will
become better understood with regard to the following description, appended
claims, and accompanying drawings which illustrate exemplary features of the
invention. However, it is to be understood that each of the features can be
used in
the invention in general, not merely in the context of the particular
drawings, and
the invention includes any combination of these features, where:
Figure 1A is a schematic sectional side view of a version of an
aerosolization apparatus in a rest position;
Figure 1B is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure 1A just before capsule puncture;
Figure 1C is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure 1A as the capsule is being punctured;
Figure 1D is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure 1A just after capsule puncture;
'~5 Figure 1E is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure 1A in use;
Figure 2A is a schematic sectional side view of another version of an
aerosolization apparatus in a rest position;
Figure 2B is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure ZA just before capsule puncture;
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
Figure 2C is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure 2A as the capsule is being punctured;
Figure 2D is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure 2A just after capsule puncture;
Figure 2E is a schematic sectional side view of the version of an
aerosolization apparatus shown in Figure 2A in use;
Figure 3 is a graph showing the effectiveness of using an alignment
guide according to the present invention; and
Figure 4 is a schematic perspective view of a version of an alignment
guide.
DESCRIPTION
The present invention relates to an aerosolization apparatus. In
particular, the invention relates to an aerosolization apparatus capable of
aerosolizing a powder contained in a capsule. Although the process is
illustrated in
the context of aerosolizing a dry powder pharmaceutical formulation for
inhalation,
the present invention can be used in other processes and should not be limited
to the
examples provided herein.
An aerosolization apparatus 100 according to the present invention is
shown schematically in Figure 1A. The aerosolization apparatus 100 comprises a
housing 105 defining a chamber 110 having one or more air inlets 115 and one
or
more air outlets 120. The chamber 110 is sized to receive a capsule 125 which
contains an aerosolizable pharmaceutical formulation. A puncturing mechanism
130 comprises an alignment guide 132 having a seating surface 133 and a
passageway 134 in which a puncture member 135 is slidably received. Near or
adjacent the outlet 120 is an end section 140 that may be sized and shaped to
be
received in a user's mouth or nose so that the user may inhale through an
opening
145 in the end section 140 that is in communication with the outlet 120.
The aerosolization apparatus 100 utilizes air flowing through the
chamber 110 to aerosolize the pharmaceutical formulation in the capsule 125.
For
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-6-
example, Figures 1A through 1E illustrate the operation of a version of an
aerosolization apparatus 100 where air flowing through the inlet 115 is used
to
aerosolize the pharmaceutical formulation and the aerosolized pharmaceutical
formulation flows through the outlet 120 so that it may be delivered to the
user
through the opening 145 in the end section 140. The aerosolization apparatus
100
is shown in its initial condition in Figure 1A. The capsule 125 is positioned
within
the chamber 110 and the pharmaceutical formulation is contained within the
capsule 125.
To use the aerosolization apparatus 100, the pharmaceutical
formulation in the capsule 125 is exposed to allow it to be aerosolized. In
the
version of Figures 1A though 1E, the puncture mechanism 130 is advanced within
the chamber 110 by applying a force 150 to the puncture mechanism 130.
Initially,
the alignment guide 132 and the puncture member 135 advance as a unit to the
position shown in Figure 113. In this position, the seating surface 133
contacts the
capsule 125 to center the capsule 125 on the alignment guide 132. For example,
a
user may press against a surface of the puncturing mechanism 130 to cause the
puncturing mechanism 130 to slide within the housing 105. )3y continuing to
apply
the force 150, the puncture member 135 is advanced into and through the wall
of
the capsule 1259 as shown in Figure 1C. The puncture member may comprise one
or more sharpened tips 152 to facilitate the advancement through the wall of
the
capsule 125. The puncturing mechanism 130 is then retracted to the position
shown
in Figure 1I~, leaving an opening 160 through the wall of the capsule 125 to
expose
the pharmaceutical formulation in the capsule 125.
Air or other gas then flows through an inlet 115, as shown by arrows
165 in Figure 1E. The flow of air causes the pharmaceutical formulation to be
aerosolized. When the user inhales 170 through the end section 140 the
aerosolized
pharmaceutical formulation is delivered to the user's respiratory tract. In
one
version, the air flow 165 may be caused by the user's inhalation 170. In
another
version, compressed air or other gas may be ejected into the inlet 115 to
cause the
aerosolizing air flow 165.
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
Proper creation of the opening 160 in the capsule 125 allows for
efficient and effective delivery of the aerosolized pharmaceutical formulation
to the
user. In contrast, improper creation of the opening 160 can lead to
inefficient and
less effective delivery of the medicament to a user. Therefore a properly
sharpened
tip 152 can help in the creation of consistent openings in the capsule. Also,
it is
important to have the sharpened tip 152 properly aligned with the capsule 125
to
assure proper creation of the opening 160.
Accordingly, to increase the efficiency and effectiveness of the
aerosolization apparatus 100, the alignment guide 132 may be designed to
improve
capsule alignment. In one version, the seating surface 133 is positioned so
that at
least a portion of the surface is at an angle, a, relative to a transverse
axis of greater
than 35 degrees, more preferably from 35 degrees to 55 degrees, more
preferably
from 40 degrees to 53 degrees, and most preferably about 45 degrees.
Conventional alignment guides, such as those available from PI3~T Pharma in
Milan, Italy, and those described in PCT application VV~ 02/03220 which is
incorporated herein by reference in its entirety, have an angle, a, less than
33
degrees. The increased angle, a, of the seating surface 133 provides a
decreased
angle, b, relative to the longitudinal axis of the capsule 125 and/or the
longitudinal
axis of the chamber 110 and/or the longitudinal axis of the puncture member
135.
The angle, b, of the seating surface 133 relative to one or more of these axes
is
preferably less than 55 degrees, more preferably from 35 degrees to 55
degrees,
more preferably from 37 degrees to 50 degrees, and most preferably about 45
degrees. It has been unexpectedly discovered, that the increased angle, a, of
the
seating surface 133 significantly improves capsule alignment and unexpectedly
extends the effective lifetime of the aerosolization apparatus 100.
A version of an aerosolization apparatus 100 comprising an
alignment guide 132 according to the present invention is shown in Figures 2A
through 2E. In this version, the housing 105 of the aerosolization apparatus
100 ,
comprises a body 205 and a removable endpiece 210. The endpiece 210 may be
removed from the body 205 to insert a capsule 125 in the chamber 110 which is
formed when the body 205 and the endpiece 210 are connected together. The
endpiece 210 comprises a partition 215 that blocks the forward end of the
chamber
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
_g_
110, and the partition 215 has the one or more outlets 120 extending
therethrough.
An example of an aerosolization apparatus with a partition 215 and chamber 110
is
described in U.S. Patent 4,069,819 and in U.S. Patent 4,995,385, both of which
are
incorporated herein by reference in their entireties. In such an arrangement,
the
chamber 110 comprises a longitudinal axis that lies generally in the
inhalation
direction, and the capsule 125 is insertable lengthwise into the chamber 110
so that
the capsule's longitudinal axis may be parallel to the longitudinal axis of
the
chamber 110. In the version of Figures 2A through 2E, the chamber 110 is sized
to
receive a capsule 125 containing a pharmaceutical formulation in a manner
which
allows the capsule to move within the chamber 110. The inlets 115 comprise a
plurality of tangentially oriented slots 220. When a user inhales 170 through
the
endpiece 210, outside air is caused to flow through the tangential slots 220
as
shown by arrows 225 in Figure 2E. This airflow 225 creates a swirling airflow
within the chamber 110. The swirling airflow causes the capsule 125 to contact
the
partition 215 and then to move within the chamber 110 in a manner that causes
the
pharmaceutical formulation to exit the capsule 125 and become entrained within
the
swirling airflow. In one version, the capsule 125 may rotate within the
chamber
110 in a manner where the longitudinal axis of the capsule is remains at an
angle
less than 80 degrees, and preferably less than 45 degrees from the
longitudinal axis
of the chamber. The movement of the capsule 125 in the chamber 110 may be
caused by the width of the chamber 110 being less than the length of the
capsule
125. In one specific version, the chamber 110 comprises a tapered section 230
that
terminates at an edge 235. 1?uring the flow of swirling air in the chamber
110, the
forward end of the capsule 125 contacts and rests on the partition 215 and a
sidewall of the capsule 125 contacts the edge 235 and slides andJor rotates
along the
edge 235. This motion of the capsule is particularly effective in forcing a
large
amount of the pharmaceutical formulation through one or more openings 160 in
the
rear of the capsule 125.
The one or more openings 160 in the rear of the capsule 125 in the
version of Figures 2A through 2E are created by a puncturing mechanism 130
having a puncture member 135 such as any of those described above that is
slidable
within the body 205. The puncturing mechanism 130, shown in its rest position
in
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-9-
Figure 2A, comprises a plunger 240 attached at its forward end 245 to the
puncture
member 135, which in the version shown is a U-shaped staple 250 having two
sharpened tips 152 as in any version described above or the like. The
puncturing
mechanism 130 further comprises a alignment member 255 which contacts the
plunger 240 andlor the puncture member 135 and is slidable relative to the
plunger
240 and the puncture member 135. To create the openings 160 in the capsule
125,
the user applies a force 150 to the plunger 240, as shown in Figure 2B, such
as by
pressing against the end surface 155 of the plunger 240 with the user's finger
or
thumb. The force 150 causes the plunger to slide within the body 205. A slight
frictional contact between the plunger 240 the a rear section 260 of the
alignment
member 255 causes the alignment member 255 to also slide within the body 205
until a forward seating surface 265 of the alignment member 255 contacts the
capsule 125, as shown in Figure 2B. The forward seating surface 265, which may
be angled at an angle, a, as discussed above, contacts capsule 125 and secures
the
capsule 125 between the alignment member 255 and the partition 215. The
continued application of force 150 causes the plunger 240 and the puncture
member
135 to slide relative to the alignment member 255, as shown in Figure 2C, to
advance the puncture member 135 through openings 270 in the forward seating
surface 265 and into the capsule 125. Upon the removal of the force 150, a
spring
275 or other biasing member urges the puncturing mechanism 130 back to its
rest
position. For example, the spring 275 may contact a shoulder 2~0 in the body
205
and press a flange 2g5 on the plunger 240 toward a rim 290 in the body 205.
The
frictional engagement between the plunger 240 and the alignment member 255
also
returns the alignment member 255 to its retracted position when the plunger is
returned to its retracted position.
In another version, the aerosolization apparatus 100 may be
configured differently than as shown in Figures 1A through 1D and 2A through
2E.
For example, the chamber 100 may be sized and shaped to receive the capsule
125
so that the capsule 125 is orthogonal to the inhalation direction, as
described in U.S.
Patent 3,991,761. As also described in U.S. Patent 3,991,761, the puncturing
mechanism 130 may puncture both ends of the capsule 125. In such version, the
puncture member 135 of the present invention may be provided to puncture one
or
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-10-
both ends of the capsule 125. In another version, the chamber may receive the
capsule 125 in a manner where air flows through the capsule 125 as described
for
example in U.S. Patent 4,338,931 and in U.S. Patent 5,619,985. In another
version,
the aerosolization of the pharmaceutical formulation may be accomplished by
pressurized gas flowing through the inlets, as described for example in
US Patent 5,458,135, U.S. Patent 5,785,049, and U.S. Patent 6,257,233, or
propellant, as described in PCT Publication WO 00172904 and U.S, Patent
4,114,615. All of the above references being incorporated herein by reference
in
their entireties.
Figure 3 graphically illustrates the advantages using an alignment
guide 132 according to the present invention. The diamonds show the resulting
emitted dose using a conventional alignment guide having a seating surface
with an
angle, a, less than 33 degrees. As can be seen, the device loses effectiveness
after
about 20 actuations. however, the alignment guide having a seating surface
having
an angle, a, of about 45 degrees provides effective use even after 80
actuations, as
shown by the circles and squares.
Another version of an aligmr~ent guide 132 is shown in Figure 4. In
this version, the seating surface 133 comprises one or more protrusions, such
as ribs
300, that serve to contact the capsule during the puncturing process. The ribs
300
create troughs 305 into which residual powder pharmaceutical formulation may
deposit. ~y providing the troughs 305 and thereby reducing the amount of
residual
powder on the portion of the seating surface 133 that contacts the capsule,
the
effectiveness of the aerosolization apparatus is improved and the lifetime of
the
aerosolization apparatus is extended. The ribs 300 may extend longitudinally,
as
shown, and/or may extend in an orthogonal direction. In one version,
longitudinally extending ribs 300, as shown, are at an angle, a, as described
above.
The surface of the seating surface 133 and/or the ribs 300 may comprise a low
friction material to further reduce the wear on the surface. Alternatively or
additionally, the protrusions may be in the form of other raised.portions such
as
bumps and/or the troughs may be formed by indentations, such as divots or
valleys,
into the surface.
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-11-
In a preferred version, the invention provides a system and method
for aerosolizing a pharmaceutical formulation and delivering the
pharmaceutical
formulation to the respiratory tract of the user, and in particular to the
lungs of the
user. The pharmaceutical formulation may comprise powdered medicaments,
liquid solutions or suspensions, and the like, and may include an active
agent.
The active agent described herein includes an agent, drug,
compound, composition of matter or mixture thereof which provides some
pharmacologic, often beneficial, effect. This includes foods, food
supplements,
nutrients, drugs, vaccines, vitamins, and other beneficial agents. As used
herein,
the terms further include any physiologically or pharmacologically active
substance
that produces a localized or systemic effect in a patient. An active agent for
incorporation in the pharmaceutical formulation described herein may be an
inorganic or an organic compound, including, without limitation, drugs which
act
on: the peripheral nerves, adrenergic receptors, cholinergic receptors, the
skeletal
muscles, the cardiovascular system, smooth muscles, the bl~od circulatory
system,
synoptic sites, neuroeffector functional sites, endocrine and hormone systems,
the
immunological system, the reproductive system, the skeletal system, autacoid
systems, the alimentary and excretory systems, the histamine system, and the
central nervous system. Suitable active agents may be selected from, for
example,
hypnotics and sedatives, psychic energizers, tranquilizers, respiratory drugs,
anticonvulsants, muscle relaxants, antiparkinson agents (dopamine
antagnonists),
analgesics, anti-inflammatories, antianxiety drugs (anxiolytics), appetite
suppressants, antimigraine agents, muscle contractants, anti-infectives
(antibiotics,
antivirals, antifungals, vaccines) antiarthritics, antimalarials, antiemetics,
anepileptics, bronchodilators, cytokines, growth factors, anti-cancer agents,
antithrombotic agents, antihypertensives, cardiovascular drugs,
antiarrhythmics,
antioxicants, anti-asthma agents, hormonal agents including contraceptives,
sympathomimetics, diuretics, lipid regulating agents, antiandrogenic agents,
antiparasitics, anticoagulants, neoplastics, antineoplastics, hypoglycemics,
nutritional agents and supplements, growth supplements, antienteritis agents,
vaccines, antibodies, diagnostic agents, and contrasting agents. The active
agent,
when administered by inhalation, may act locally or systemically.
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-12-
The active agent may fall into one of a number of structural classes,
including but not limited to small molecules, peptides, polypeptides,
proteins,
polysaccharides, steroids, proteins capable of eliciting physiological
effects,
nucleotides, oligonucleotides, polynucleotides, fats, electrolytes, and the
like.
Examples of active agents suitable for use in this invention include
but are not limited to one or more of calcitonin, amphotericin B,
erythropoietin
(EPO), Factor VIII, Factor IX, ceredase, cerezyme, cyclosporin, granulocyte
colony
stimulating factor (GCSF), thrombopoietin (TPO), alpha-1 proteinase inhibitor,
elcatonin, granulocyte macrophage colony stimulating factor (GMCSF), growth
hormone, human growth hormone (HGH), growth hormone releasing hormone
(GHRH), heparin, low molecular weight heparin (LMWH), interferon alpha,
interferon beta, interferon gamma, interleukin-1 receptor, interleukin-2,
interleukin-
1 receptor antagonist, interleukin-3, interleukin-4, interleukin-6,
luteinizing
hormone releasing hormone (LHRH), factor Ice, insulin, pro-insulin, insulin
analogues (e.g., mono-acylated insulin as descubed in jJ.S. Patent loo.
5,922,675,
which is incorporated herein by reference in its entirety), amylin, C-peptide,
somatostatin, somatostatin analogs including octreotide, vasopressin, follicle
stimulating hormone (FSH), insulin-like growth factor (IGF), insulintropin,
macrophage colony stimulating factor (M-CSF), nerve growth factor (1liGF),
tissue
growth factors, keratinocyte growth factor (I~GF), glial growth factor (GGF),
tumor
necrosis factor (T1~IF), ,endothelial growth factors, parathyroid hormone
(PTH),
glucagon-like peptide thymosin alpha l, IIb/IIIa inhibitor, alpha-1
antitrypsin,
phosphodiesterase (PIKE) compounds, VLA-4 inhibitors, bisphosponates,
respiratory syncytial virus antibody, cystic fibrosis transmembrane regulator
(CFTR) gene, deoxyreibonuclease (I~nase), bactericidal/permeability increasing
protein (BPI), anti-CMV antibody, 13-cis retinoic acid, macrolides such as
erythromycin, oleandomycin, troleandomycin, roxithromycin, clarithromycin,
davercin, azithromycin, flurithromycin, dirithromycin, josamycin, spiromycin,
midecamycin, leucomycin, miocamycin, rokitamycin, andazithromycin, and
swinolide A; fluoroquinolones such as ciprofloxacin, ofloxacin, levofloxacin,
trovafloxacin, alatrofloxacin, moxifloxicin, norfloxacin, enoxacin,
grepafloxacin,
gatifloxacin, lomefloxacin, sparfloxacin, temafloxacin, pefloxacin,
amifloxacin,
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-13-
fleroxacin, tosufloxacin, prulifloxacin, irloxacin, pazufloxacin,
clinafloxacin, and
sitafloxacin, aminoglycosides such as gentamicin, netilmicin, paramecin,
tobramycin, amikacin, kanamycin, neomycin, and streptomycin, vancomycin,
teicoplanin, rampolanin, mideplanin, colistin, daptomycin, gramicidin,
colistimethate, polymixins such as polymixin B, capreomycin, bacitracin,
penems;
penicillins including penicllinase-sensitive agents like penicillin G,
penicillin V,
penicillinase-resistant agents like methicillin, oxacillin, cloxacillin,
dicloxacillin,
floxacillin, nafcillin; gram negative microorganism active agents like
ampicillin,
amoxicillin, and hetacillin, cillin, and galampicillin; antipseudomonal
penicillins
like carbenicillin, ticarcillin, azlocillin, mezlocillin, and piperacillin;
cephalosporins
like cefpodoxime, cefprozil, ceftbuten, ceftizoxime, ceftriaxone, cephalothin,
cephapirin, cephalexin, cephradrine, cefoxitin, cefamandole, cefazolin,
cephaloridine, cefaclor, cefadroxil, cephaloglycin, cefuroxime, ceforanide,
cefotaxime, cefatrizine, cephacetrile, cefepime, cefixime, cefonicid,
cefoperazone,
cefotetan, cefmetazole, ceftazidime, loracarbef, and moxalactam, monobactams
like
aztreonam; and carbapenems such as imipenem, meropenem, pentan~idine
isethiouate, albuterol sulfate, lidocaine, metaproterenol sulfate,
beclomethasone
diprepionate, triamcinolone acetamide, budesonide acetonide, fluticasone,
ipratropium bromide, flunisolide, cromolyn sodium, ergotaixiine tartrate and
where
applicable, analogues, agonists, antagonists, inhibitors, and pharmaceutically
acceptable salt forms of the above. In reference to peptides and proteins, the
invention is intended to encompass synthetic, native, glycosylated,
unglycosylated,
pegylated forms, and biologically active fragments and analogs thereof.
Active agents for use in the invention further include nucleic acids,
as bare nucleic acid molecules, vectors, associated viral particles, plasmid
DNA or
RNA or other nucleic acid constructions of a type suitable for transfection or
transformation of cells, i.e., suitable for gene therapy including antisense.
Further,
an active agent may comprise live attenuated or killed viruses suitable for
use as
vaccines. Other useful drugs include those listed within the Physician's Desk
Reference (most recent edition).
The amount of active agent in the pharmaceutical formulation will
be that amount necessary to deliver a therapeutically effective amount of the
active
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-14-
agent per unit dose to achieve the desired result. In practice, this will vary
widely
depending upon the particular agent, its activity, the severity of the
condition to be
treated, the patient population, dosing requirements, and the desired
therapeutic
effect. The composition will generally contain anywhere from about 1 % by
weight
to about 99% by weight active agent, typically from about 2% to about 95% by
weight active agent, and more typically from about 5% to 85% by weight active
agent, and will also depend upon the relative amounts of additives contained
in the
composition. The compositions of the invention are particularly useful for
active
agents that are delivered in doses of from 0.001 mg/day to 100 mg/day,
preferably
in doses from 0.01 mg/day to 75 mg/day, and more preferably in doses from 0.10
mg/day to 50 mg/day. It is to be understood that more than one active agent
may
be incorporated into the formulations described herein and that the use of the
term
"agent" in no way excludes the use of two or more such agents.
The pharmaceutical formulation may comprise a pharmaceutically
acceptable excipient or carrier which may be taken into the lungs with no
significant adverse toxicological effects to the subject, and particularly to
the lungs
of the subject. In addition to the active agent, a pharmaceutical formulation
may
optionally include one or more pharmaceutical excipients which are suitable
for
pulmonary administration. These excipients, if present, are generally present
in the
composition in amounts ranging from about 0.01 % to about 95% percent by
weight, preferably from about 0.5 to about 80%, and more preferably from about
1
to about 60% by weight. Preferably, such excipients will, in part, serve to
further
improve the features of the active agent composition, for example by providing
more efficient and reproducible delivery of the active agent, improving the
handling characteristics of powders, such as flowability and consistency,
and/or
facilitating manufacturing and filling of unit dosage forms. In particular,
excipient
materials can often function to further improve the physical and chemical
stability
of the active agent, minimize the residual moisture content and hinder
moisture
uptake, and to enhance particle size, degree of aggregation, particle surface
properties, such as rugosity, ease of inhalation, and the targeting of
particles to the
lung. One or more excipients may also be provided to serve as bulking agents
when
it is desired to reduce the concentration of active agent in the formulation.
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-15-
Pharmaceutical excipients and additives useful in the present
pharmaceutical formulation include but are not limited to amino acids,
peptides,
proteins, non-biological polymers, biological polymers, carbohydrates, such as
sugars, derivatized sugars such as alditols, aldonic acids, esterified sugars,
and
sugar polymers, which may be present singly or in combination. Suitable
excipients are those provided in WO 96/32096, which is incorporated herein by
reference in its entirety. The excipient may have a glass transition
temperature
(Tg) above about 35° C, preferably above about 40 °C, more
preferably above 45°
C, most preferably above about 55 °C.
Exemplary protein excipients include albumins such as human serum
albumin (HSA), recombinant human albumin (rHA), gelatin, casein, hemoglobin,
and the like. Suitable amino acids (outside of the dileucyl-peptides of the
invention), which may also function in a buffering capacity, include alanine,
glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine,
lysine,
leucine, isoleucine, valine, methionine, phenylalanine, aspartame, tyrosine,
tryptophan, and the like. Preferred are amino acids and polypeptides that
function
as dispersing agents. Amino acids falling into this category include
hydrophobic
amino acids such as leucine, valine, isoleucine, tryptophan, alanine,
methionine,
phenylalanine, tyrosine, histidine, and proline. I~ispersibility- enhancing
peptide
excipients include dimers, trimers, tetramers, and pentamers composing one or
more hydrophobic amino acid components such as those described above.
Carbohydrate excipients suitable for use in the invention include, for
example, monosaccharides such as fructose, maltose, galactose, glucose,1~-
mannose, sorbose, and the like; disaccharides, such as lactose, sucrose,
trehalose,
cellobiose, and the like; polysaccharides, such as raffinose, melezitose,
maltodextrins, dextrans, starches, and the like; and alditols, such as
mannitol,
xylitol, maltitol, lactitol, xylitol sorbitol (glucitol), pyranosyl sorbitol,
myoinositol
and the like.
The pharmaceutical formulation may also include a buffer or a pH
adjusting agent, typically a salt prepared from an organic acid or base.
Representative buffers include organic acid salts of citric acid, ascorbic
acid,
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-16-
gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or
phthalic
acid, Tris, tromethamine hydrochloride, or phosphate buffers.
The pharmaceutical formulation may also include polymeric
excipients/additives, e.g., polyvinylpyrrolidones, derivatized celluloses such
as
hydroxymethylcellulose, hydroxyethylcellulose, and
hydroxypropylmethylcellulose, Ficolls (a polymeric sugar), hydroxyethylstarch,
dextrates (e.g., cyclodextrins, such as 2-hydroxypropyl-(3-cyclodextrin and
sulfobutylether-(3-cyclodextrin), polyethylene glycols, and pectin.
The pharmaceutical formulation may further include flavoring
agents, taste-masking agents, inorganic salts (for example sodium chloride),
antimicrobial agents (for example benzalkonium chloride), sweeteners,
antioxidants, antistatic agents, surfactants (for example polysorbates such as
"TWEEN 20" and "TWEEN 80"), sorbitan esters, lipids (for example
phospholipids such as lecithin and other phosphandylcholines,
phosphatidylethanolamines), fatty acids and fatty esters, steroids (for
example
cholesterol), and chelating agents (for example EI~TA9 zinc and other such
suitable
canons). ~ther pharmaceutical excipients and/or additives suitable for use in
the
compositions according to the invention are listed in "Remington: The Science
&
Practice of Pharmacy", 19~h ed., 5~illiams ~~ 5~a~illiams, (1995), and in the
~0 "Physician's Desk Reference", 52~d ed., Medical Economics, Montvale, N~
(1998),
both of which are incorporated herein by reference in their entireties.
"Mass median diameter" or "MMD" is a measure of mean particle
size, since the powders of the invention are generally polydisperse (i.e.,
consist of a
range of particle sizes). MMD values as reported herein are determined by
centrifugal sedimentation, although any number of commonly employed techniques
can be used for measuring mean particle size. "Mass median aerodynamic
diameter" or "MMAD" is a measure of the aerodynamic size of a dispersed
particle.
The aerodynamic diameter is used to describe an aerosolized powder in terms of
its
settling behavior, and is the diameter of a unit density sphere having the
same
settling velocity, generally in air, as the particle. The aerodynamic diameter
encompasses particle shape, density and physical size of a particle. As used
herein,
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-17-
MMAD refers to the midpoint or median of the aerodynamic particle size
distribution of an aerosolized powder determined by cascade impaction.
In one version, the powdered formulation for use in the present
invention includes a dry powder having a particle size selected to permit
penetration
into the alveoli of the lungs, that is, preferably 10 ~m mass median diameter
(MMD), preferably less than 7.5 ~,m, and most preferably less than 5 ~.m, and
usually being in the range of 0.1 p,m to 5 p,m in diameter. The delivered dose
efficiency (DDE) of these powders may be greater than 30%, more preferably
greater than 40%, more preferably greater than 50% and most preferably greater
than 60% and the aerosol particle size distribution is about 1.0 - 5.0 ~m mass
median aerodynamic diameter (MMAD), usually 1.5 - 4.5 ~m NIMAD and
preferably 1.5 - 4.0 ~m MMAD. These dry powders have a moisture content below
about 10% by weight, usually below about 5% by weight, and preferably below
about 3% by weight. Such powders are described in V6T~ 95/2413, V~~ 96/32149,
V~~ 99/16419, and ~~ 99/16422, all of which are all incorporated herein by
reference in their entireties.
In one version, as discussed above, the pharmaceutical formulation
may be contained within a capsule 125. The capsule 125 may be of a suitable
shape, size, and mateual to contain the pharmaceutical formulation and to
provide
the pharmaceutical formulation in a usable condition. For example, the capsule
may comprise a wall which comprises a material that does not adversely react
with
the pharmaceutical formulation. In addition, the wall may comprise a material
that
allows the capsule to be opened to allow the pharmaceutical formulation to be
aerosolized. In one version, the wall comprises one or more of gelatin,
hydroxypropyl methylcellulose (HPMC), polyethyleneglycol-compounded HPMC,
hydroxyproplycellulose, agar, or the like. In one version, the capsule may
comprise
telescopically adjoining sections, as described for example in LT.S. Patent
4,247,066
which is incorporated herein by reference in its entirety. The size of the
capsule
may be selected to adequately contain the dose of the pharmaceutical
formulation.
The sizes generally range from size 5 to size 000 with the outer diameters
ranging
from about 4.91 mm to 9.97 mm, the heights ranging from about 11.10 mm to
about
CA 02520265 2005-09-23
WO 2004/091707 PCT/US2004/011234
-18-
26.14 mm, and the volumes ranging from about 0.13 ml to about 1.37 ml,
respectively. Suitable capsules are available commercially from, for example,
Shionogi Qualicaps Co. in Nara, Japan and Capsugel in Greenwood, South
Carolina. After filling, a top portion may be placed over the bottom portion
to form
the a capsule shape and to contain the powder within the capsule, as described
in
U.S. Patent 4,846,876, U.S. Patent 6,357,490, and in the PCT application WO
00/07572 published on February 17, 2000, all of which are incorporated herein
by
reference in their entireties.
Although the present invention has been described in considerable
detail with regard to certain preferred versions thereof, other versions are
possible,
and alterations, permutations and equivalents of the version shown will become
apparent to those skilled in the art upon a reading of the specification and
study of
the drawings. For example, the cooperating components may be reversed or
provided in additional or fewer number. Also, the various features of the
versions
herein can be combined in various ways to provide additional versions of the
present invention. Furthermore, certain terminology has been used for the
purposes
of descriptive clarity, and not to limit the present invention. Therefore, any
appended claims should not be limited to the description of the preferred
versions
contained herein and should include all such alterations, permutations, and
equivalents as fall within the true spirit and scope of the present invention.
